Step-by-Step Interpretation of Pulmonary Function Tests: A Comprehensive Guide for Physicians

Dr Neeraj Manikath, claude.ai

Abstract

Pulmonary function tests (PFTs) represent a cornerstone of respiratory medicine, providing objective, quantifiable data essential for the diagnosis, management, and monitoring of pulmonary diseases. Despite their ubiquity in clinical practice, the interpretation of PFTs can be challenging due to the complexity of measurements, overlapping patterns, and the need to integrate results with clinical context. This review provides a structured, systematic approach to PFT interpretation for physicians, emphasizing a step-by-step methodology. We explore the physiological principles underlying each measurement, detail systematic interpretation strategies, discuss common patterns of abnormalities in various pulmonary disorders, and address special considerations for diverse patient populations. Additionally, we review recent technological advances and emerging modalities that complement traditional PFTs. By providing a comprehensive framework for PFT interpretation, this review aims to enhance clinicians' ability to accurately diagnose and manage respiratory conditions, ultimately improving patient outcomes.

Introduction

Pulmonary function testing encompasses a range of physiological measurements that assess various aspects of respiratory mechanics, gas exchange, and lung volumes. Since their introduction into clinical practice in the mid-20th century, PFTs have evolved into essential tools for the evaluation of respiratory symptoms, diagnosis of pulmonary diseases, assessment of disease severity, monitoring of disease progression, and evaluation of treatment responses.^1^

Despite their clinical importance, PFTs can be challenging to interpret due to several factors:

The complexity and interdependence of various lung function parameters
The overlap in patterns seen across different disease entities
The influence of demographic factors, body habitus, and testing conditions on results
The need to integrate PFT findings with clinical history, physical examination, and additional diagnostic modalities^2,3^

This review provides a systematic approach to PFT interpretation for physicians across various specialties who utilize these tests in their clinical practice. We emphasize a logical, sequential methodology that moves from quality assessment of the tests to integration with clinical data, facilitating accurate diagnosis and appropriate management decisions.

Basic Physiological Principles

Respiratory Mechanics

Understanding the mechanical properties of the respiratory system is fundamental to interpreting PFTs. The respiratory system comprises the lungs and chest wall, which function together to facilitate ventilation.^4^

Key mechanical principles include:

Elastic Properties:

The lungs have a natural tendency to collapse (elastic recoil) due to elastin fibers and alveolar surface tension.
The chest wall has a natural tendency to expand outward.
At functional residual capacity (FRC), these opposing forces balance.^5^

Airway Resistance:

Resistance to airflow through the tracheobronchial tree follows Poiseuille's law, being inversely proportional to the fourth power of airway radius.
Small changes in airway caliber (due to bronchospasm, inflammation, or mucus) can significantly increase resistance.^6^

Work of Breathing:

Comprises work against elastic forces (compliance) and resistive forces (airway resistance).
Increases in diseases affecting either component.^7^

Lung Volumes and Capacities

Lung volumes reflect the mechanical properties of the respiratory system and are often altered in specific patterns by different pathologies:^8^

Static Volumes:

Total Lung Capacity (TLC): The volume of air in the lungs after maximal inspiration.
Vital Capacity (VC): The maximum volume of air exhaled from full inspiration to full expiration.
Residual Volume (RV): The volume of air remaining in the lungs after maximal expiration.
Functional Residual Capacity (FRC): The volume of air in the lungs at the end of normal expiration.

Capacities (Combinations of Volumes):

Inspiratory Capacity (IC): Maximum volume of air inhaled from FRC.
Expiratory Reserve Volume (ERV): Maximum volume of air exhaled from FRC.

Gas Exchange

The primary function of the respiratory system is gas exchange, which depends on:^9^

Ventilation:

The process of air movement into and out of the lungs.
Measured as minute ventilation (VE): the product of tidal volume and respiratory rate.

Diffusion:

The movement of gases across the alveolar-capillary membrane.
Depends on membrane thickness, surface area, and gas solubility.

Perfusion:

Blood flow through the pulmonary capillaries.
Affects ventilation-perfusion matching, crucial for efficient gas exchange.

These physiological principles form the foundation for understanding the various measurements obtained during pulmonary function testing and their alterations in disease states.

Components of Comprehensive Pulmonary Function Testing

Spirometry

Spirometry measures the volume and flow of air during forced breathing maneuvers and is often the first-line PFT performed.^10^

Key Parameters:

Forced Vital Capacity (FVC): Maximum volume of air forcefully exhaled after maximal inspiration.
Forced Expiratory Volume in 1 second (FEV₁): Volume exhaled during the first second of an FVC maneuver.
FEV₁/FVC ratio: The proportion of the vital capacity exhaled in the first second.
Forced Expiratory Flow between 25% and 75% of FVC (FEF₂₅₋₇₅): Average flow rate during the middle half of the FVC maneuver, reflecting small airway function.
Peak Expiratory Flow (PEF): Maximum flow achieved during forced expiration.

Technical Considerations:

Requires patient cooperation and effort.
Standardized techniques and equipment calibration are crucial.
Multiple maneuvers (minimum three) with the two best efforts within 150 mL of each other for both FEV₁ and FVC.^11^

Lung Volumes

While spirometry measures dynamic lung volumes, additional tests are needed to measure static lung volumes, particularly residual volume (RV).^12^

Measurement Techniques:

Gas Dilution Methods:

Helium dilution: Uses a closed circuit with a known concentration of helium.
Nitrogen washout: Measures the volume of nitrogen washed out of the lungs during breathing of 100% oxygen.
Limited by inability to measure non-ventilated areas of the lung.

Body Plethysmography:

Uses Boyle's law to calculate lung volumes based on pressure changes.
Can measure total thoracic gas volume, including non-ventilated regions.
Generally considered the gold standard, especially in patients with obstructive diseases.^13^

Diffusion Capacity

The diffusing capacity for carbon monoxide (DLCO) assesses the transfer of gases across the alveolar-capillary membrane.^14^

Measurement:

Single-breath technique: Patient inhales a gas mixture containing a small amount of CO, holds breath for approximately 10 seconds, then exhales.
The rate of CO uptake by the blood is measured.

Physiologic Determinants:

Alveolar-capillary membrane surface area
Membrane thickness
Capillary blood volume
Hemoglobin concentration
Ventilation-perfusion matching

Bronchodilator Response

Assessing response to bronchodilators helps distinguish between fixed and reversible airflow obstruction.^15^

Procedure:

Baseline spirometry, followed by administration of a short-acting bronchodilator.
Repeat spirometry after appropriate waiting period (typically 15-20 minutes).

Significant Response:

Increase in FEV₁ and/or FVC ≥ 12% and ≥ 200 mL from baseline.^16^
Some patients with asthma may not demonstrate immediate reversibility during testing.

Bronchial Challenge Testing

These tests assess airway hyperreactivity by measuring the response to inhaled bronchoconstrictive stimuli.^17^

Methods:

Direct challenges: Using methacholine or histamine to directly stimulate airway smooth muscle.
Indirect challenges: Using exercise, mannitol, or hypertonic saline to trigger releases of endogenous mediators.

Interpretation:

Based on the provocative concentration (PC₂₀) or dose (PD₂₀) causing a 20% fall in FEV₁.
Greater sensitivity indicates higher degree of airway hyperresponsiveness.

Cardiopulmonary Exercise Testing

Cardiopulmonary exercise testing (CPET) evaluates the integrated response of the respiratory, cardiovascular, and muscular systems to exercise.^18^

Measurements:

Oxygen consumption (VO₂)
Carbon dioxide production (VCO₂)
Minute ventilation (VE)
Heart rate, blood pressure, ECG
Oxygen saturation

Clinical Utility:

Differentiating between cardiac and pulmonary causes of exercise limitation
Evaluating unexplained dyspnea
Assessing functional capacity before lung resection or transplantation
Developing exercise prescriptions for pulmonary rehabilitation

Systematic Approach to PFT Interpretation

Step 1: Assess Test Quality and Reproducibility

Before interpreting any results, evaluation of test quality is essential:^19^

Spirometry Quality Criteria:

Good start of test (extrapolated volume < 5% of FVC or 0.15 L, whichever is greater)
Smooth, continuous exhalation
Adequate duration (≥ 6 seconds or volume plateau)
Free from artifacts (coughing, glottis closure, early termination)
Reproducibility between best efforts (within 150 mL for FEV₁ and FVC)

Lung Volumes Quality Assessment:

Stable baseline breathing pattern
Adequate equilibration time for gas dilution methods
Proper panting technique for plethysmography

DLCO Quality Considerations:

Proper breath-hold time (10 ± 2 seconds)
Adequate inspiration (> 85% of VC)
Smooth, unforced exhalation
Absence of leaks during breath-hold

Step 2: Evaluate Reference Values and Lower Limits of Normal

PFT results are compared to predicted values based on demographic characteristics:^20^

Key Points:

Modern reference equations (e.g., Global Lung Function Initiative [GLI]) account for age, sex, height, and ethnicity.^21^
Lower limit of normal (LLN) represents the 5th percentile of the reference population.
Using percent predicted can be misleading, especially at extremes of age.
Z-scores (number of standard deviations from the mean) provide more accurate assessment across different parameters and patient groups.^22^

Step 3: Identify Ventilatory Pattern

The first major classification of PFT abnormalities is into restrictive, obstructive, or mixed patterns:^23^

Obstructive Pattern:

Reduced FEV₁/FVC ratio below LLN
FEV₁ typically reduced
FVC may be normal or reduced
Flow-volume loop shows concave appearance of expiratory limb

Restrictive Pattern:

Normal or increased FEV₁/FVC ratio
Reduced FVC
Reduced TLC (required for definitive diagnosis)
Flow-volume loop shows normal shape but reduced amplitude

Mixed Pattern:

Features of both obstruction and restriction
Reduced FEV₁/FVC ratio
Reduced TLC
Often requires comprehensive testing for proper identification

Step 4: Assess Severity

The degree of abnormality guides management decisions and prognostication:^24^

Obstruction Severity (Based on FEV₁ % Predicted):

Mild: > 70%
Moderate: 60-69%
Moderately Severe: 50-59%
Severe: 35-49%
Very Severe: < 35%

Restriction Severity (Based on TLC % Predicted):

Mild: 70-79%
Moderate: 60-69%
Moderately Severe: 50-59%
Severe: < 50%

Step 5: Evaluate Specific Measurements

Lung Volumes Analysis:

TLC, RV, and RV/TLC ratio provide insights into hyperinflation and air trapping.
Elevated RV with normal TLC suggests air trapping with preserved lung volume.
Elevated RV/TLC ratio (> 40%) indicates air trapping.^25^

DLCO Interpretation:

Reduced DLCO: Suggests parenchymal disease, pulmonary vascular disease, or anemia.
Elevated DLCO: Seen in alveolar hemorrhage, polycythemia, or left-to-right shunts.
DLCO/VA (KCO, transfer coefficient): Helps distinguish between loss of alveolar units and diffusion impairment.^26^

Bronchodilator Response:

Positive response suggests asthma but can occur in COPD.
Lack of acute response doesn't exclude asthma or potential benefit from bronchodilator therapy.^27^

Step 6: Analyze Flow-Volume Loops

Visual inspection of flow-volume loops provides valuable information:^28^

Normal Flow-Volume Loop:

Rapid rise to peak flow, followed by smooth, convex descent.
Inspiratory limb is semicircular.

Obstructive Patterns:

Concave expiratory limb ("scooping").
Peak flow may be reduced.
Inspiratory limb typically normal.

Restrictive Patterns:

Normal shape but reduced amplitude of both limbs.
Higher peak flow relative to FVC compared to normal.

Upper Airway Obstruction Patterns:

Fixed obstruction: Flattening of both inspiratory and expiratory limbs.
Variable extrathoracic obstruction: Flattened inspiratory limb.
Variable intrathoracic obstruction: Flattened expiratory limb.^29^

Step 7: Integrate with Clinical Information

PFT results should never be interpreted in isolation:^30^

Clinical Context:

Symptoms: Dyspnea, cough, wheezing, sputum production
Risk factors: Smoking history, occupational exposures, environmental exposures
Comorbidities: Cardiac disease, neuromuscular disorders, connective tissue diseases
Medication history: Bronchodilators, inhaled or systemic corticosteroids

Additional Diagnostic Data:

Imaging findings (chest radiograph, CT scan)
Laboratory results (e.g., alpha-1 antitrypsin levels, inflammatory markers)
Previous PFT results for assessing progression or response to therapy

Common Patterns of Disease

Obstructive Lung Diseases

Asthma:

Reduced FEV₁/FVC ratio
Often significant bronchodilator responsiveness
Potentially normal between exacerbations
Increased RV/TLC ratio during exacerbations
Normal or mildly reduced DLCO
Positive bronchial challenge tests^31^

Chronic Obstructive Pulmonary Disease (COPD):

Persistent reduction in FEV₁/FVC ratio
Limited bronchodilator responsiveness
Air trapping (increased RV and RV/TLC ratio)
Reduced DLCO, particularly in emphysema
Progressive decline in FEV₁ over time^32^

Bronchiectasis:

Variable obstruction pattern
May show bronchodilator responsiveness
Often normal DLCO unless extensive disease
Less air trapping than emphysema^33^

Restrictive Lung Diseases

Interstitial Lung Diseases (ILD):

Reduced TLC, FVC, and FEV₁ with preserved or increased FEV₁/FVC ratio
Reduced DLCO (often disproportionate to lung volume reduction)
Decreased compliance
Exercise-induced desaturation^34^

Neuromuscular Disorders:

Reduced TLC, FVC, and FEV₁ with preserved or increased FEV₁/FVC ratio
Normal DLCO when corrected for alveolar volume
Potentially reduced maximum inspiratory and expiratory pressures (MIP and MEP)
May show supine decline in FVC (diaphragmatic weakness)^35^

Chest Wall Disorders (e.g., Kyphoscoliosis):

Reduced TLC, FVC, and FEV₁ with preserved or increased FEV₁/FVC ratio
DLCO usually normal when corrected for alveolar volume
Reduced compliance of the respiratory system^36^

Mixed Patterns

Combined Pulmonary Fibrosis and Emphysema (CPFE):

Near-normal spirometry despite significant disease
Preserved lung volumes due to opposing effects
Severely reduced DLCO
Exercise limitation with desaturation^37^

Bronchiolitis Obliterans Following Lung Transplantation:

Progressive airflow obstruction
Air trapping
Minimal bronchodilator response
Flow-volume loop showing concave expiratory limb^38^

Special Patterns

Upper Airway Obstruction:

May have normal spirometry values despite significant symptoms
Characteristic flow-volume loop abnormalities
Reduced PEF disproportionate to FEV₁ reduction
Potentially normal TLC and DLCO^39^

Pulmonary Vascular Diseases:

Often normal spirometry and lung volumes
Reduced DLCO, sometimes severely
Exercise limitation with desaturation
Reduced oxygen pulse on CPET^40^

Special Considerations for Specific Patient Populations

Elderly Patients

The aging lung presents several physiological changes that affect PFT interpretation:^41^

Age-Related Changes:

Decreased elastic recoil
Increased chest wall stiffness
Increased RV and RV/TLC ratio
Decreased FEV₁/FVC ratio

Interpretation Challenges:

Using age-appropriate reference equations is essential.
LLN becomes more relevant than percent predicted.
Comorbidities more common and may affect results.
Cognitive and physical limitations may affect test performance.

Pediatric Population

Children present unique considerations in PFT performance and interpretation:^42^

Developmental Aspects:

Lung and airway growth continuing through adolescence
Reference equations specific to pediatric populations required
Z-scores preferred over percent predicted

Technical Considerations:

Age-appropriate instructions and encouragement
Modified acceptance criteria in younger children
Alternative techniques for preschool children (impulse oscillometry, specific airway resistance)

Obesity

Obesity significantly impacts lung function and PFT interpretation:^43^

Physiologic Effects:

Reduced chest wall compliance
Increased work of breathing
Decreased ERV and FRC
Relatively preserved TLC
Potentially decreased DLCO due to altered blood volume

Interpretation Adjustments:

Body mass index (BMI) consideration in reference equations
Assessment of respiratory muscle strength may be helpful
Evaluation of respiratory symptoms during exertion

Pre-operative Evaluation

PFTs play a critical role in assessing surgical risk, particularly for thoracic procedures:^44^

Lung Resection Surgery:

FEV₁ and DLCO as initial assessments
Predicted post-operative values calculated based on planned resection
CPET for comprehensive evaluation in high-risk patients
Split function studies (ventilation/perfusion scans) to assess regional contribution

Non-thoracic Surgery:

Assessment of respiratory reserve
Identification of reversible abnormalities
Baseline for postoperative comparison
Risk stratification for postoperative pulmonary complications

Pitfalls in PFT Interpretation

Technical and Procedural Issues

Multiple factors can affect test quality and results:^45^

Common Problems:

Suboptimal effort or cooperation
Improper mouthpiece technique (leaks, tongue obstruction)
Volume or flow sensor calibration errors
Incorrect demographic data entry
Temperature or altitude corrections not applied
Failure to follow standardized procedures

Recognition:

Inspect flow-volume loops and volume-time curves for abnormalities
Check repeatability between maneuvers
Verify demographic information accuracy

Misclassification of Patterns

Several scenarios can lead to pattern misclassification:^46^

Pseudo-restriction:

Occurs when obstruction with air trapping reduces FVC
TLC measurement necessary to distinguish from true restriction
Often seen in poorly controlled asthma or COPD exacerbations

Pseudo-obstruction:

Poor inspiratory effort before forced expiration
Failure to exhale completely
Upper airway issues mimicking small airway obstruction

Missed Mixed Patterns:

Relying solely on spirometry
Not accounting for air trapping
Overlooking DLCO abnormalities

Interpretive Challenges

Several clinical scenarios present unique interpretive challenges:^47^

Early or Mild Disease:

Values near LLN may represent early disease or normal variation
Longitudinal testing valuable for detecting subtle changes
Integration with symptoms and risk factors crucial

Discordance Between Tests:

Conflicting results between different PFT components
Requires comprehensive clinical evaluation
May indicate unusual pathophysiology or technical issues

Border Zone Cases:

Results falling between established patterns
Small deviations from LLN
Often benefit from additional diagnostic modalities

Integrating PFTs with Other Diagnostic Modalities

Imaging Correlation

Combining PFTs with imaging enhances diagnostic accuracy:^48^

Chest Radiography:

Limited sensitivity for early disease
Provides basic structural information
May explain some PFT abnormalities

High-Resolution Computed Tomography (HRCT):

Superior for detecting and characterizing parenchymal abnormalities
Essential in ILD evaluation
Can explain discordant PFT findings
Quantitative CT increasingly used to correlate with function

Laboratory Studies

Specific biomarkers may complement PFT findings:^49^

Relevant Tests:

Alpha-1 antitrypsin levels in early-onset emphysema
Inflammatory markers in systemic inflammatory conditions
Specific autoantibodies in connective tissue disease-associated ILD
Brain natriuretic peptide (BNP) in heart failure mimicking respiratory limitation

Advanced Physiological Testing

Additional tests may clarify difficult cases:^50^

Specialized Assessments:

Impulse oscillometry for small airway function
Negative expiratory pressure (NEP) technique for dynamic hyperinflation
Multiple breath nitrogen washout for ventilation inhomogeneity
Exhaled nitric oxide (FeNO) for eosinophilic airway inflammation

Technological Advances and Future Directions

Emerging Technologies

Recent innovations are expanding PFT capabilities:^51^

Advanced Modalities:

Forced oscillation technique (FOT) for respiratory impedance measurement
Structured light plethysmography for non-contact assessment of breathing patterns
Electrical impedance tomography for regional ventilation assessment
Machine learning algorithms for pattern recognition in complex PFT data

Wearable Monitoring:

Home spirometry devices with cloud connectivity
Continuous monitoring of respiratory parameters
Integration with electronic health records
Remote supervision of testing quality

Artificial Intelligence in PFT Interpretation

AI applications show promise for enhancing PFT interpretation:^52^

Potential Applications:

Automated quality control assessment
Pattern recognition beyond traditional categories
Integration of multi-modal data (PFTs, imaging, clinical variables)
Prediction of disease progression and treatment response

Current Limitations:

Need for large, diverse training datasets
Validation in varied clinical settings
Integration into clinical workflows
Regulatory considerations

Conclusion

Pulmonary function testing remains a cornerstone of respiratory medicine, providing objective data crucial for diagnosis, management, and monitoring of pulmonary diseases. A systematic, step-by-step approach to PFT interpretation, as outlined in this review, enhances diagnostic accuracy and clinical decision-making.

The integration of traditional PFTs with newer technologies and advanced modalities promises to further refine our understanding of respiratory physiology and pathophysiology. As we continue to develop more sophisticated analytical approaches and incorporate artificial intelligence, the diagnostic yield and clinical utility of PFTs will likely expand.

However, the fundamental principle remains unchanged: PFT interpretation should never occur in isolation but must be integrated with clinical history, physical examination findings, imaging results, and other diagnostic modalities to provide comprehensive respiratory assessment. By following a systematic approach and understanding both the capabilities and limitations of these tests, clinicians can optimize their use of PFTs to improve patient care and outcomes.

References

Kaminsky DA. What does airway resistance tell us about lung function? Respir Care. 2012;57(1):85-96.
Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948-968.
Ruppel GL, Enright PL. Pulmonary function testing. Respir Care. 2012;57(1):165-175.
Lutfi MF. The physiological basis and clinical significance of lung volume measurements. Multidiscip Respir Med. 2017;12:3.
Ionescu CM. The human respiratory system: an analysis of the interplay between anatomy, structure, breathing and fractal dynamics. Springer; 2013.
Bates JHT, Irvin CG. Measuring lung function in mice: the phenotyping uncertainty principle. J Appl Physiol. 2003;94(4):1297-1306.
Lumb AB. Nunn's Applied Respiratory Physiology. 8th ed. Elsevier; 2017.
Criée CP, Sorichter S, Smith HJ, et al. Body plethysmography – its principles and clinical use. Respir Med. 2011;105(7):959-971.
Wagner PD. The physiological basis of pulmonary gas exchange: implications for clinical interpretation of arterial blood gases. Eur Respir J. 2015;45(1):227-243.
Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338.
Graham BL, Steenbruggen I, Miller MR, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200(8):e70-e88.
Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3):511-522.
Stocks J, Quanjer PH. Reference values for residual volume, functional residual capacity and total lung capacity. ATS Workshop on Lung Volume Measurements. Official statement of the European Respiratory Society. Eur Respir J. 1995;8(3):492-506.
Graham BL, Brusasco V, Burgos F, et al. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur Respir J. 2017;49(1):1600016.
Pellegrino R, Rodarte JR, Brusasco V. Assessing the reversibility of airway obstruction. Chest. 1998;114(6):1607-1612.
Calverley PMA, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003;58(8):659-664.
Coates AL, Wanger J, Cockcroft DW, et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J. 2017;49(5):1601526.
Guazzi M, Adams V, Conraads V, et al. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation. 2012;126(18):2261-2274.
Enright PL. How to make sure your spirometry tests are of good quality. Respir Care. 2003;48(8):773-776.
Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324-1343.
Stanojevic S, Wade A, Stocks J, et al. Reference ranges for spirometry across all ages: a new approach. Am J Respir Crit Care Med. 2008;177(3):253-260.
Culver BH, Graham BL, Coates AL, et al. Recommendations for a standardized pulmonary function report. An Official American Thoracic Society Technical Statement. Am J Respir Crit Care Med. 2017;196(11):1463-1472.
Hyatt RE, Scanlon PD, Nakamura M. Interpretation of Pulmonary Function Tests: A Practical Guide. 4th ed. Lippincott Williams & Wilkins; 2014.
Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2023 Report. 2023.
O'Donnell DE, Laveneziana P. The clinical importance of dynamic lung hyperinflation in COPD. COPD. 2006;3(4):219-232.
Hughes JMB, Pride NB. Examination of the carbon monoxide diffusing capacity (DLco) in relation to its KCO and VA components. Am J Respir Crit Care Med. 2012;186(2):132-139.
Postma DS, Rabe KF. The Asthma-COPD Overlap Syndrome. N Engl J Med. 2015;373(13):1241-1249.
Johns DP, Pierce R. Pocket Guide to Spirometry. 3rd ed. McGraw Hill Australia; 2011.
Miller RD, Hyatt RE. Evaluation of obstructing lesions of the trachea and larynx by flow-volume loops. Am Rev Respir Dis. 1973;108(3):475-481.
Crapo RO. Pulmonary-function testing. N Engl J Med. 1994;331(1):25-30.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2023 Update.
Agusti A, Calverley PMA, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.
King PT. The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis. 2009;4:411-419.
Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(5):e44-e68.
Fitting JW. Sniff nasal inspiratory pressure: simple or too simple? Eur Respir J. 2006;27(5):881-883.
Caro CG, Butler J, DuBois AB. Some effects of restriction of chest cage expansion on pulmonary function in man: an experimental study. J Clin Invest. 1960;39:573-583.
Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005;26(4):586-593.
Meyer KC, Raghu G, Verleden GM, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J. 2014;44(6):1479-1503.
Watson MA, King CS, Holley AB, Greenburg DL, Mikita JA. Clinical and lung-function variables associated with vocal cord dysfunction. Respir Care. 2009;54(4):467-473.
Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42-D50.
Sharma G, Goodwin J. Effect of aging on respiratory system physiology and immunology. Clin Interv Aging. 2006;1(3):253-260.
Beydon N, Davis SD, Lombardi E, et al. An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children.

manikath

Tuesday, April 15, 2025